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Abstract
For extracellular vesicle research, whether for biomarker
discoveries or therapeutic applications, it is critical to have
high-quality samples. Both microscopy and NanoSight
Tracking Analysis (NTA) for size distribution have been
used to detect large vesicles. However, there is currently no
well-established method that is convenient for routine
quality analysis of small-size impurities in vesicle samples.
In this paper we report a convenient method, called ‘size-
exclusion high-performance liquid chromatography’ (SE-
HPLC), alongside NTA and Microscopy analysis to guide
and qualify the isolation and processing of vesicles. First,
the SE-HPLC analysis was used to detect impurities of
small-size proteins during the ultra-centrifugation process
of vesicle isolation; it was then employed to test the changes
of vesicles under different pH conditions or integrity after
storage. As SE-HPLC is generally accessible in most
institutions, it could be used as a routine means to assist
researchers in examining the integrity and quality of
extracellular vesicles along with other techniques either
during isolation/preparation or for further engineering and
storage.
Keywords extracellular vesicles, exosomes, HPLC, quality
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1. Introduction
Exosomes and extracellular vesicles are secreted by most
cell types under both normal and pathological conditions
[1, 2, 3]. These vesicles have been detected in a wide range
of biological fluids, such as blood, urine, saliva, and breast
milk [4, 5, 6, 7]. Carrying abundant biomolecules like
proteins, RNAs and lipids, they are important messengers
in intercellular communications and play a pivotal role in
tumour progression and metastasis, as well as other
diseases [8]. In addition to efforts to understand the biology
of exosomes and extracellular vesicles in different diseases,
extensive attention has recently also been focused on the
study of these nanoparticles as biomarkers and the engi‐
neering of vehicles for drug and gene delivery. All such
research, which has used different approaches including
proteomics [9, 10, 11], transcriptomics [10, 11], lipidomics
[10, 12], and vesicle engineering [13, 14], demands samples
of high quality.
However, current isolation and characterization methods
leave much to be desired in terms of ensuring high-quality
vesicles. Various methods have been used for vesicle
isolation, including ultracentrifugation [15], size exclusion
(filtration or chromatography) [15, 16, 17, 18, 19], immu‐
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noaffinity isolation [15, 20], precipitation (ExoQuick or
“salting-out”) [21, 22], or combinations of these. Each
method yields different results and standardization has not
yet been established – though the vesicle research com‐
munity is working hard on this [23]. A few techniques have
been commonly used to characterize isolated vesicles, such
as Transmission Electron Microscopy (TEM) or Cryo-EM
[24], Nanoparticle Tracking Analysis (NTA, NanoSight)
[25], and Western Blot for protein marker confirmation [15].
Recently, Webber et al. proposed the use of the ratio of
vesicle counts to protein concentration as an indirect means
to check the purity of vesicle preparation [26]. All these
approaches are based on the presence of vesicular particles
and present some limitations and challenges. For example,
electron microscopy was employed to give informative
visualization of vesicular morphology and identify the
presence of larger-non-vesicular particulates. NTA re‐
quires a lot of optimization of parameters and presents
several challenges related for example to detection thresh‐
old, minimum expected particle size, blur, and minimum
track length [25]. On the other hand, for impurity detection,
while presence of protein biomarkers not expressed by
vesicles [26] was proposed for quality assay, the selection
of these markers is challenging and may not be accurate
due to the limited understanding of how proteins are
packaged into vesicles.
To ensure high-quality vesicles, not only must the desired
population of particles be confirmed to be present, con‐
taminants and impurities must also be demonstrated to be
absent. Unfortunately, there is no easy method available to
rule out the presence of contaminants. Thus, in this paper
we report a simple SE-HPLC analysis to detect water-
soluble small-size proteins in samples. SE-HPLC is widely
used and accessible in most institutions and could be used
alongside other current techniques to characterize these
exosomes and extracellular vesicles. It could confer a
routine and a convenient means to qualify the vesicle
products.
2. Materials and Methods
2.1 Materials
Chemicals or reagents were purchased from commercial
sources and used without further processing unless
otherwise stated. Research-grade foetal bovine serum (FBS,
sterile triple 100 nm filtered) and DMEM cell-culture media
were purchased from Fisher Scientific. MDA (MDA-
MB-231 human breast adenocarcinoma) and MSTO
(MSTO-211H human biphasic mesothelioma) cell lines
were from ATCC (Manassas, VA). Sephadex G-25 Nap-5
columns were purchased from GE Healthcare. The ultra-
centrifugation was performed on a Beckman Coulter
Optima LE-80K ultra-centrifuge with an SW28 rotor. High-
performance liquid chromatography (HPLC) was per‐
formed on an Agilent 1260 Infinity system equipped with
an auto-sampler and a variable wavelength UV detector.
The HPLC column was a size-exclusion column (Superose
12 10/300 GL from GE Healthcare) (9 µm-13 µm). The Gel
Filtration HMW Calibration Kits were purchased from GE
Healthcare and the liposome labelled with DiO (120 nm)
for calibration was prepared in-house by Dr Alexander
Klibanov. A NanoSight NS300 system (Malvern Instru‐
ments Inc., Westborough, MA) and a Tecnai F20 Twin
transmission electron microscope (FEI, Hillsboro, OR) were
used to characterize the vesicle samples.
3. Methods
3.1 Cell Culture
Cells, including MDA and MSTO, were cultured at 37°C at
5% CO2 in DMEM media complemented with 4% vesicle-
depleted FBS. The FBS was depleted of vesicles by over‐
night ultra-centrifugation at 120,000 g followed by filtration
through PVDF 0.22 µm vacuum-driven filters (Millipore).
The cell-culture supernatant was collected for vesicle
isolation when cell confluence reached 90% (usually after
days, from cell seeding to final supernatant collection).
3.2 Isolation of Vesicles
Vesicles were isolated from cell-culture supernatants or the
commercially available FBS. The isolating procedure was
adapted from a reported protocol [15] with minor modifi‐
cations. Briefly, to remove large cell debris the collected
cell-culture supernatant was first subjected to subsequent
centrifugations at 400 g for 5 min and 3000 g for 30 min,
followed by sequential filtration through 0.45 µm and 0.22
µm PVDF filters. FBS was used as purchased. The liquid
was further ultra-centrifuged at 120,000 g at 4℃ for 90
minutes, followed by removal of the supernatant. The
vesicle pellet was subjected to washing by re-suspending
in a large volume of fresh DPBS (30 mL) and ultra-centri‐
fuging at 120,000 g at 4℃ for 90 minutes. This washing step
was repeated several times and aliquots from each round
of ultra-centrifugation were saved for HPLC analysis and
other assays, as shown in Scheme 1. Aliquots of final vesicle
pellets were used for experiments immediately or stored at
4℃ for future use.
3.3 Size-exclusion HPLC Analysis
Size-exclusion HPLC (SE-HPLC) was performed with a
Superose 12 10/300 GL column with exclusion limit of 2×
106 Daltons to detect the contaminants and vesicular
nanoparticles. 50-100 µL of an aliquot was injected via the
auto-sampler. The mobile phase was DPBS solution (137
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4)
with a flow rate of 1.0 ml/min. UV absorbance was detected
at a wavelength of 254 nm.
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3.4 Cryogenic Transmission Electron Microscopy (cryo-TEM)
Analysis
Vesicles were vitrified by standard methods of cryo-TEM
[27]. In brief, an aliquot (~3.5 µl) was applied to a glow-
discharged, perforated carbon-coated grid, manually
blotted with filter paper, and rapidly plunged into liquid
ethane. The grids were stored in liquid nitrogen, then
transferred to a Gatan 626 cryo-specimen holder and
maintained at -180°C. Low-dose images were collected at a
nominal magnification of 29,000× on a Tecnai F20 Twin
transmission electron microscope operating at 120 kV. The
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Scheme 1. Flow chart of vesicle isolation and purification based on
differential ultra- centrifugation combined with filtration. SE-HPLC was
used to qualify the intermediates and final product as well.
3.5 NanoSight Particle Analysis
Real-time nanoparticle detection, counting and sizing were
performed on the NS-300 NanoSight Instrument following
manufacturer protocols. The instrument settings were as
follows: camera type – sCMOS; shutter length – varied;
shutter setting – 1300; camera gain – 512; frame rate –
varied; analysis – blur setting, minimal expected size,
minimal track length, all set to automatic. The version of
the software was NTA 2.3.
3.6 Proteins and ELISA Analyses
Total protein of isolated vesicles and fractions from HPLC
were measured using the Micro BCATM protein assay kit
(Thermo Scientific Pierce, Rockford, IL) following the
protocol provided by the manufacturer, while the two
protein markers, CD63 and CD9, were confirmed by using
an enzyme-linked immunoassay kit (ELISA, System
Biosciences, Mountain View, CA). All measurements were
performed following the protocol provided by the manu‐
facturers.
3.7 SE-HPLC Detection of Small-size Impurities in Vesicles at
Different pHs or in Refrigerated Storage
The possible changes of vesicles under different pH
conditions were evaluated by using SE-HPLC analysis. The
buffer medium of purified vesicles was changed from PBS
to sodium acetate (0.1M, pH5) or sodium bicarbonate
(0.1M, pH9) by using NAP-5 column. Aliquots (about
5×108 particle/mL) were kept at room temperature and
analysed by SE-HPLC over time.
To test the possible changes of vesicles in refrigerated
storage, an aliquot of vesicles in PBS buffer (pH7.4) was
stored at 4°C for up to one month, during which vesicles
were analysed weekly by SE-HPLC for possible appear‐
ance of small-size impurities, and by Nanosight analysis for
the changes of size distribution.
4. Results and Discussion
For research seeking to understand the biology of exosomes
and extracellular vesicles, to discover biomarkers, especial‐
ly proteomins, lipidomics and genomics, and to engineer
these vesicles for drug and gene delivery, it is crucial to
ensure high-quality samples by removing interfering
contaminants such as non-vesicular proteins or other
biological molecules of small size. To that end, a simple
means for quality analysis of vesicle samples is highly
desirable. Although several techniques, such as microsco‐
py and NTA, can give visual information on particle size
and global size distribution, respectively, there is still no
easy technique to detect impurities of small size. Size
chromotagraphy has been used for isolation or purification
of extracellular vesicles with different gel mediums, but no
real HPL analysis has been reported for quality assay
(Abstract P-IV-13 at ISEV 2015: Journal of Extracellular
Vesicles, 2015,4: 27783). In this paper, we demonstrate that
size-exclusion HPLC (SE-HPLC) could be a convenient
method to detect proteins and other impurities of small
size.
The size-exclusion column used in this study was first
calibrated using standard Gel Filtration HMW Calibration
Kits (purchased from GE Healthcare) and nano-sized
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liposomes. The void volume of this column was deter‐
mined using Blue Dextran 2000 (molecular weight 2000
kDa) to be at 8 min and 4 sec at a flow rate of 1 mL/min.
Further confirmed by DiO-labelled liposomes (120 nm),
components eluting before 8 min were not resolved since
they were within the void volume. Proteins as big as
Thyroglobumin and Ferritin can be resolved on this column
(see details in supporting materials), so it is selected to
separate non-associated proteins and other smaller impur‐
ities from vesicles.
Several techniques have been used to isolate vesicles. In this
study, sequential ultra-centrifugation was employed to
prepare vesicles from MSTO, MDA tumour cells and FBS,
and the samples were analysed by SE-HPLC. According to
the ultra-centrifugation protocol [15], three rounds of ultra-
centrifugations (70 min each run) were used to isolate and
purify vesicles from cell-conditioned media. Since the
procedure is empirical, the reproducibility of high-quality
vesicles remains an issue. By introducing SE-HPLC to
separate and detect vesicles and free small-size proteins,
we were able to analyse the aliquot at different centrifuging
levels in the whole process. As demonstrated in Fig. 1, after
two rounds of ultra-centrifugation, the species eluting out
of the column before 10 min were negligible in the mixture
compared to those appearing after 10 min. After the third
round of ultra-centrifugation, the peak with the retention
time of 7.5 min (identified as vesicle peak as shown in Fig
2) became more dominant while other peaks after 10 min
were decreased. With one more round of washing and
ultra-centrifugation, a single peak was observed at 7.5 min,
which represented the final vesicle product. All three kinds
of vesicles from different sources (FBS, MSTO, MDA)
showed similar patterns in HPLC analysis for this ultra-
centrifugation process.
The vesicle samples representing the single peak in SE-
HPLC were subjected to cryo-TEM and NanoSight analysis
(Fig. 2). In TEM, these vesicles appeared as well-defined
membrane-bound vesicles ranging in size from 30 to 150
nm in all three kinds of vesicle. NanoSight analysis gave a
more broad distribution of 40 to 200 nm. To further confirm
the identity of the samples representing the different peaks
in SE-HPLC, fractions at 7.5 min and 12.8 min were
collected and examined by cryo-TEM and ELISA for the
presence of extracellular protein markers CD63 and CD9.
The results showed that the fraction at 7.5 min was extrac‐
ellular-vesicles positive in both CD63 and CD9, while the
fraction sample at 12.8 min was not positive in either of
these.
In recent years, nano-sized extracellular vesicles have
emerged as potential drug- and gene-delivery carriers,
where nano-sized vesicles may need to be subjected to pH
conditions other than the physiological one (pH 7.2-7.4). To
test for any changes in vesicles under different pH condi‐
tions, the buffer for vesicle samples was changed from PBS
(pH7.4) to sodium acetate buffer (pH5) or sodium bicar‐
bonate buffer (pH9). The SE-HPLC analyses were per‐
formed at different times. As illustrated in Fig. 3, FBS
vesicles showed a response to pH changes, with intensity
of vesicle peak continuously decreasing while that of newly
generated peaks increased in the study period. Although
the details of these new peaks are not known, and further
identification is challenging and beyond the focus of the
Figure 1. Representative chromatograms of extracellular vesicles from MSTO cell-culture supernatant. Aliquots after one (A), two (B), three (C) and four (D)
ultra-centrifugations were analysed. The peak with a retention time of 7.5 min stands for the exosome particles while the other peaks are impurities of small
size.
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current study, it is apparent that changes did happen in
these vesicles. These new impurity peaks might be due to
the vesicular particles disrupted or the proteins or other
biomolecules of small size falling off from the vesicles,
resulting the lower and lower signal from the vesicles.
Nevertheless, we have demonstrated that it would be
useful to use SE-HPLC to detect impurities or changes of
vesicles under different conditions.
Another question for vesicle research regards the appro‐
priate storage condition for vesicle samples. Generally,
-80oC has been recommended [23] for long-term storage.
However, the cycle of “freeze and thaw”, if it happens
frequently, may do harm to membrane vesicles. Is it safe to
keep the vesicles at 4°C, and how long will they remain
good? As illustrated in Fig. 4, aliquots of purified MDA
vesicles in PBS were kept at 4°C for up to one month and
there was no obvious change in the SE-HPLC graph. The
NTA analysis also showed minimum changes of size in
these samples. The other two vesicle samples from MSTO
cells and FBS showed similar results, without any substan‐
tial changes in size distribution and small-size impurities.
These results suggest that it may be safe to keep vesicle
aliquots in a refrigerator for a short period of up to four
weeks. However, our SE-HPLC evidence only implies
physical stability as particulates at 4°C. To draw conclu‐
sions about the biological functions of these extracellular
vesicles after storage, further evaluation is required.
It is important to note that there are also several limitations
related to this HPLC detection technique. First, in our
study, no detailed information on vesicle size is gained by
Figure 2. Characterization of purified extracellular vesicles isolated from FBS (A), MSTO cells (B), and MDA cells (C). Representative Cryogenic Transmission
Electron images of vesicles show round-shape membrane-bound particles from all three sources (FBS, MSTO and MDA cells; left column) with occasional
irregularly distributed electron-dense content, both inside and on the surface of the membrane. The NanoSight plots depict typical size distributions of
extracellular vesicles from the above-described sources (right column). Bars correspond to 100 nm.
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HPLC analysis alone, since this column cannot resolve
nanoparticles of different size. All nanoparticles elute at the
void volume as demonstrated by calibrations where Blue
Dextran 2000 (2, 000 k Daltons) and DiO-labelled liposomes
of size 120 nm were used to determine the void volume
under the same condition used for vesicle samples (shown
Figure 3. Chromatograms of FBS vesicles in (A) bicarbonate buffer (0.1M, pH9) and (B) acetate buffer (0.1M, pH5). From top to bottom in both A and B, the
time point was 0h, 1h, 2h, 4h and overnight (14h), respectively.
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in supporting materials). The intention of this study was to
test whether SE-HPLC can be used as a means of quality
analysis of soluble proteins and other impurities of small
size. For a detailed size measurement by HPLC, more
evaluations are needed. It would be best to use the simple
and straightforward SE-HPLC to qualify the vesicle
preparation followed by other characterizations such as
TEM, NTA, western blot and flow cytometry. Secondly, a
high exclusion limit of 2x106 Daltons was used in this study
to give a wide detection range and better resolution of small
impurities for the extracellular vesicles of size less than
around 200 nm. Other exclusion limit ranges may give
different results, depending on the vesicles and the sources
to prepare these vesicles. From our experience, size-
exclusion columns with higher exclusion limits may be able
to resolve large particles but will give less desirable
resolution of small-size molecules. Therefore, it is impor‐
tant to choose an appropriate column and calibrate it with
a series of molecules of different sizes. Finally, these results
were based on the ultra-centrifugation purification method
using commercially available FBS and tumour cells. For
biomarker discovery research dealing with real samples of
blood, etc., different isolation techniques such as affinity
selection, filtration, or others, as well as any combinations
of these could be employed to generate particular types of
vesicles. Nonetheless, purity of samples would be the top
priority to avoid false biomarkers due to impurities.
Therefore, in addition to quality-analysis techniques (NTA
as a global analysis of size distribution) to exclude large
particles or aggregates, techniques such as the HPLC
analysis reported here represent a convenient complemen‐
tary means to detect impurities of small size.
5. Conclusions
In this study, we conclude that size-exclusion HPLC
analysis can be used to help determine the purity of
extracellular vesicle samples by detecting proteins and
other impurities of small size that can have a substantial
impact on biomarker discovery. This method has been used
to examine the purity of vesicular nanoparticles with
changes in pH and under storage at 4°C. The results
exemplify the potential of such HPLC analysis to monitor
vesicle disruption during storage, modification or other
processes in extracellular vesicle research focusing on
biomarker discovery or therapeutic application.
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Figure 4. Representative chromatograms of MDA vesicles stored at 4°C for one month. The top was fresh aliquot and the bottom was aged for one month in
a 4°C refrigerator.
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